Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Circulating tissue factor and thrombosis.

U Rauch1, Y Nemerson

  • 1Department of Medicine, Mount Sinai School of Medicine, New York, New York 10029, USA.

Current Opinion in Hematology
|August 29, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Alternatively spliced tissue factor and full-length tissue factor protect cardiomyocytes against TNF-α-induced apoptosis.

Journal of molecular and cellular cardiology·2012
Same author

The microenvironment in chronic pancreatitis and pancreatic cancer induces neuronal plasticity.

Neurogastroenterology and motility·2009
Same author

Long-term clopidogrel administration following severe coronary injury reduces proliferation and inflammation via inhibition of nuclear factor-kappaB and activator protein 1 activation in pigs.

European journal of clinical investigation·2009
Same author

Regulation of cardiomyocyte full-length tissue factor expression and microparticle release under inflammatory conditions in vitro.

Journal of thrombosis and haemostasis : JTH·2009
Same author

High molecular weight adiponectin correlates positively with myeloperoxidase in patients with type 2 diabetes mellitus.

Diabetes research and clinical practice·2008
Same author

SR proteins ASF/SF2 and SRp55 participate in tissue factor biosynthesis in human monocytic cells.

Journal of thrombosis and haemostasis : JTH·2008
Same journal

Dynamic myeloid suppressor states in cancer and inflammation and their therapeutic potential.

Current opinion in hematology·2026
Same journal

Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning.

Current opinion in hematology·2026
Same journal

Nutrition as a regulator of hematopoietic stem cell biology and transplantation.

Current opinion in hematology·2026
Same journal

From biomimicry to clinical actionability: rethinking high-shear thrombosis as a mechanobiological system.

Current opinion in hematology·2026
Same journal

Bidirectional relationship between metabolic and thrombotic disease mechanisms.

Current opinion in hematology·2026
Same journal

The dual role of the brain-derived neurotrophic factor as a regulator of hemostasis and thrombotic risk.

Current opinion in hematology·2026
See all related articles

Tissue factor (TF) in blood contributes to myocardial infarction. Our research shows TF on circulating microparticles actively promotes clot formation, highlighting its thrombogenic potential.

Area of Science:

  • Cardiovascular Biology
  • Hemostasis and Thrombosis
  • Biomedical Engineering

Background:

  • Circulating microparticles carrying tissue factor (TF) are implicated in myocardial infarction.
  • Understanding the thrombogenic potential of blood-borne TF is crucial for cardiovascular disease research.

Purpose of the Study:

  • To investigate the thrombogenic activity of tissue factor (TF) present on circulating microparticles.
  • To develop experimental systems for studying blood-borne TF's role in thrombus formation.

Main Methods:

  • Developed perfusion systems using collagen-coated slides and pig arterial media to model thrombus development.
  • Utilized immunostaining to detect TF in developing thrombi.
  • Assessed TF activity by observing fibrin deposition and thrombotic mass.

Related Experiment Videos

  • Investigated the role of leukocyte-derived particles and adhesion proteins in platelet interactions.

    • Main Results:

    • Thrombi formed on TF-free substrates immunostained positive for TF, indicating its deposition from blood.
    • Fibrin deposition and overall thrombotic mass were significantly reduced by a TF inhibitor, confirming TF's active role.
    • Leukocyte-derived particles were observed to attach to platelets via adhesion proteins.

    Conclusions:

    • Blood-borne tissue factor actively contributes to thrombus formation, playing a significant role in thrombotic events like myocardial infarction.
    • The developed experimental systems effectively demonstrate the thrombogenic potential of circulating TF.
    • Leukocyte-platelet interactions mediated by adhesion proteins are a key component of the observed thrombotic process.